thiotepa has been researched along with Agnogenic Myeloid Metaplasia in 7 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30." | 1.62 | Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. ( Angelucci, E; Bacigalupo, A; Barosi, G; Bregante, S; Casarino, L; Chiusolo, P; De Stefano, V; Di Grazia, C; Dominietto, A; Giammarco, S; Gualandi, F; Guolo, F; Lamparelli, T; Laurenti, L; Metafuni, E; Raiola, AM; Rossi, E; Rossi, M; Sica, S; Signori, A; Sora, F; Vannucchi, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Li, XY | 1 |
| Huang, K | 1 |
| Xu, HG | 1 |
| Shen, L | 1 |
| Zhan, LP | 1 |
| Wu, ZZ | 1 |
| Wu, XJ | 1 |
| Huang, QW | 1 |
| Huang, WQ | 1 |
| Cheng, B | 1 |
| Fang, JP | 1 |
| Shouval, R | 1 |
| Vega, Y | 1 |
| Fein, JA | 1 |
| Danylesko, I | 1 |
| Shem Tov, N | 1 |
| Yerushalmi, R | 1 |
| Sobas, M | 1 |
| Czyż, A | 1 |
| Nagler, A | 1 |
| Shimoni, A | 1 |
| Memoli, M | 1 |
| Paviglianiti, A | 1 |
| Malard, F | 1 |
| Battipaglia, G | 2 |
| Brissot, E | 1 |
| Médiavilla, C | 1 |
| Bianchessi, A | 1 |
| Banet, A | 1 |
| Van de Wyngaert, Z | 1 |
| Ledraa, T | 1 |
| Belhocine, R | 1 |
| Sestili, S | 1 |
| Lapusan, S | 1 |
| Hirsch, P | 1 |
| Favale, F | 1 |
| Boussaroque, A | 1 |
| Bonnin, A | 1 |
| Vekhoff, A | 1 |
| Legrand, O | 1 |
| Mohty, M | 2 |
| Duléry, R | 1 |
| Chiusolo, P | 2 |
| Bregante, S | 3 |
| Giammarco, S | 1 |
| Lamparelli, T | 2 |
| Casarino, L | 1 |
| Dominietto, A | 1 |
| Raiola, AM | 1 |
| Metafuni, E | 1 |
| Di Grazia, C | 1 |
| Gualandi, F | 2 |
| Sora, F | 1 |
| Laurenti, L | 1 |
| Sica, S | 1 |
| Barosi, G | 1 |
| Guolo, F | 1 |
| Rossi, M | 1 |
| Rossi, E | 1 |
| Vannucchi, A | 1 |
| Signori, A | 1 |
| De Stefano, V | 1 |
| Bacigalupo, A | 3 |
| Angelucci, E | 2 |
| Mauff, K | 1 |
| Wendel, L | 1 |
| Arcese, W | 1 |
| Santarone, S | 1 |
| Rubio, MT | 1 |
| Kroger, N | 1 |
| Fox, ML | 1 |
| Blaise, D | 1 |
| Iori, AP | 1 |
| Fanin, R | 2 |
| Chalandon, Y | 1 |
| Pioltelli, P | 1 |
| Marotta, G | 1 |
| Sever, M | 1 |
| Solano, C | 1 |
| Contentin, N | 1 |
| de Wreede, LC | 1 |
| Czerw, T | 1 |
| Hernandez-Boluda, JC | 1 |
| Hayden, P | 1 |
| McLornan, D | 1 |
| Yakoub-Agha, I | 1 |
| Patriarca, F | 1 |
| Masciulli, A | 1 |
| Pavoni, C | 1 |
| Finazzi, MC | 1 |
| Bosi, A | 1 |
| Russo, D | 1 |
| Narni, F | 1 |
| Messina, G | 1 |
| Alessandrino, EP | 1 |
| Carella, AM | 1 |
| Milone, G | 1 |
| Bruno, B | 2 |
| Mammoliti, S | 1 |
| Bonifazi, F | 1 |
| Rambaldi, A | 1 |
| Van Lint, MT | 1 |
| Valbonesi, M | 1 |
| Lercari, G | 1 |
| Carlier, P | 1 |
| Occhini, D | 1 |
| Valeriani, A | 1 |
| Piaggio, G | 1 |
| Pitto, A | 1 |
| Benvenuto, F | 1 |
| Figari, O | 1 |
| De Stefano, G | 1 |
| Caimo, A | 1 |
| Sessarego, M | 1 |
2 trials available for thiotepa and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Tr | 2019 |
Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone M | 1996 |
5 other studies available for thiotepa and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
[Cord blood transplantation with thiotepa containing myeloablative conditioning in a case of pediatric primary myelofibrosis].
Topics: Child; Cord Blood Stem Cell Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Primar | 2022 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibro | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middl | 2021 |
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic S | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neopl | 2021 |